GESCO SE
GSC1
ISIN DE000A1K0201 / Valor 13790258
GESCO SE
UMushroom community rating:
About company
GESCO SE is a long-term investor that specializes in acquiring successful industrial SMEs, with a focus on building a strong group of market and technology leaders known as "hidden champions." Founded in 1989, GESCO went public in 1998 and its shares are listed in the Prime Standard. The company's approach is long-term oriented and sustainable, aiming to continue proven business models while developing them further to maximize growth potential and ensure the future of the Group. By creating added value for shareholders, employees, customers, suppliers, and business partners, GESCO SE strives to maintain its position as a leading player in the industrial sector.
Summarized from source with an LLMView SourceSector: IndustrialsLatest Results (06.02.2026):
GESCO SE — Q3 2025 (covering 1 Jan–30 Sep 2025): the Group delivered stable sales but improved profitability in the first nine months of 2025. Sales fell to €364.7m (−4.7% YoY) while EBITDA rose to €28.2m and EBIT to €15.3m, producing group earnings after minority interests of about €8.6m and earnings per share of €0.80. The balance sheet remains strong with a 60.4% equity ratio and net debt of €46.9m; management has adjusted the full‑year outlook down in November.
Top-line and orders
Sales Q1–Q3 2025: €364.7m (−4.7% vs. prior year). Incoming orders: €375.0m (−6.4%). Book‑to‑bill ~1.03. Order backlog at 30 Sep 2025: €189.4m (down from €205.8m a year ago).
Profitability
EBITDA Q1–Q3 2025: €28.2m (margin ~7.7%). EBIT: €15.33m (up 20.4% YoY). EBT: €12.58m. Group earnings after minority interests: €8.6m. EPS: €0.80 (based on ~10.4m shares).
Segment performance
Materials Refinement & Distribution: sales €163.6m, EBIT €3.86m (ROS 2.4%). Health Care & Lifescience: sales €111.8m, EBIT €9.92m (ROS 8.9%). Industrial Assets & Infrastructure: sales €89.4m, EBIT €7.63m (ROS 8.5%).
Balance sheet and liquidity
Total assets €450.1m. Equity €271.9m → equity ratio 60.4%. Cash and cash equivalents €32.2m; unutilised credit lines €43.5m. Net debt reported €46.9m (31 Dec 2024: €42.6m).
Working capital and costs
Inventories rose to €162.2m (including Eckart); trade receivables €62.0m. Cost of materials ratio improved to 56.6% (−1.7pp YoY). Personnel expenses decreased slightly to €96.3m.
Corporate actions and scope
Acquisition: Eckart GmbH was acquired retroactive to 1 Jan 2025 and is allocated to the Industrial Assets & Infrastructure segment; this affected comparability and the cost-of-materials and order figures. Doerrenberg divestments completed end-2024 were excluded from 2025 segment composition.
Workforce
Employees (excl. trainees) at 30 Sep 2025: 1,668 (down ~10.7% YoY), reflecting disposals, efficiency measures and the Eckart acquisition.
Outlook and post‑period event
On 11 Nov 2025 management narrowed and lowered guidance: 2025 sales expected €480–500m (previously €485–515m); Group earnings (after minorities) €9–12m (previously €13–17m). Management expects special effects to weigh roughly −€1m.
Market indicators and share data
Return on sales (ROS) Q1–Q3: ~4.2%. XETRA closing price on balance‑sheet date: €15.30. GESCO emphasizes a conservative balance‑sheet policy and capacity for selective M&A and investments.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
182 M
Market cap (USD)
3,410
Daily traded volume (Shares)
13.45 / 13.2
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
